Amgen's cholesterol drug Repatha has been given the green light in Europe, making it the first in the new PCSK9 inhibitor class approved anywhere in the world. Repatha (evolocumab) is a human ...
Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback